---
document_datetime: 2026-01-21 14:54:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vacpertagen-epar-all-authorised-presentations_en.pdf
document_name: vacpertagen-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8156461
conversion_datetime: 2026-01-22 21:27:51.365152
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size            |
|------------------|-------------------|------------|--------------------------|---------------------------|----------------------------|---------------------------|----------------------|
| EU/1/25/1999/001 | VacPertagen       | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 1 pre-filled syringe |

--¹

One dose (0.5 ml) contains:

Purified Bordetella pertussis antigens Recombinant Pertussis Toxin (PTgen )¹,² 5 micrograms Filamentous Haemagglutinin (FHA)¹  5 micrograms

¹adsorbed on aluminium  hydroxide, hydrated 0.3 milligrams Al³ ⁺

²produced in Bordetella pertussis as a genetically detoxified PT (PTgen) by recombinant DNA technology

Formaldehyde may be present in trace amounts as a manufacturing process residual.